A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer
Shanghai JMT-Bio Inc.
Shanghai JMT-Bio Inc.
Fudan University
Fudan University
Rutgers, The State University of New Jersey
Tianjin Medical University Cancer Institute and Hospital
University of Kansas Medical Center
Henan Cancer Hospital
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Shandong Cancer Hospital and Institute
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Fudan University
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
The First Affiliated Hospital with Nanjing Medical University
ChineseAMS
National Institute of Oncology, Hungary